Xeris Biopharma Holdings (XERS) came into focus after raising its full year 2026 revenue outlook to a range of US$395 million to US$405 million, alongside releasing new third quarter and nine month ...
Source LinkXeris Biopharma Holdings (XERS) came into focus after raising its full year 2026 revenue outlook to a range of US$395 million to US$405 million, alongside releasing new third quarter and nine month ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.